caBozantinib in cOllectiNg ductS Renal Cell cArcInoma
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II trial (monocentric) study designed to determine To evaluate
activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria in Metastatic
Collecting Duct Renal Cell Carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano